ProShares Ultra Silver

Altimmune Inc. Common Stock

VS TR 2x Long VIX Futures ETF

MicroSectors Gold Miners 3X Leveraged ETN

ProShares Bitcoin Strategy ETF

Defiance Daily Short Digitizing the Economy ETF

ProShares Ultra VIX Short-Term Futures

ProShares Ultra DJ-AIG Crude Oi

iShares Silver Trust

Volatility Shares Trust 2x Bitcoin Strategy ETF

Direxion Daily FTSE China Bull 3X ETF

GraniteShares 1.5x Long Coinbase Daily ETF

ProShares UltraShort Silver

MicroSectors Gold Miners -3X Inverse Leveraged ETNs

KraneShares CSI China Internet ETF

VS TR -1x Short VIX Futures ETF

ProShares Trust ProShares Short Bitcoin Strategy ETF

iShares FTSE China 25 Index Fun

iShares MSCI Japan

ProShares UltraPro Dow30

Sea Limited American Depositary Shares each representing one Class A Ordinary Share

Coinbase Global Inc. Class A Common Stock

Nuvve Holding Corp. Common Stock

TeraWulf Inc. Common Stock

Canaan Inc. American Depositary Shares

JELD-WEN Holding Inc. Common Stock

Arcturus Therapeutics Holdings Inc. Common Stock

Evolus Inc. Common Stock

First Solar Inc. Common Stock

MicroAlgo Inc. Ordinary Shares

Inno Holdings Inc. Common Stock

Kindly MD Inc. Common Stock

ZK International Group Co. Ltd Ordinary Share

Rigetti Computing Inc. Common Stock

Xenon Pharmaceuticals Inc. Common Shares

Next Technology Holding Inc. Ordinary Shares

Theriva Biologics Inc. Common Stock

UnitedHealth Group Incorporated Common Stock (DE)

Bioventus Inc. Class A Common Stock

Hertz Global Holdings Inc Common Stock

Click here to get full coverage on Trend Tracker for (JANX) - news.stocktradersdaily.com

Trend Tracker for (JANX)  news.stocktradersdaily.com

Trend Tracker for (JANX) - news.stocktradersdaily.com

Click here to get full coverage on Janux Therapeutics (JANX) Reports Q1 EPS Loss, Maintains Strong Cash Position - GuruFocus

Janux Therapeutics (JANX) Reports Q1 EPS Loss, Maintains Strong Cash Position  GuruFocus

Janux Therapeutics (JANX) Reports Q1 EPS Loss, Maintains Strong Cash Position - GuruFocus

Click here to get full coverage on Janux Therapeutics, Inc. (JANX): Among Unknown Billionaire Phill Gross’ Stock Picks with Huge Upside Potential - Yahoo Finance

Janux Therapeutics, Inc. (JANX): Among Unknown Billionaire Phill Gross’ Stock Picks with Huge Upside Potential  Yahoo Finance

Janux Therapeutics, Inc. (JANX): Among Unknown Billionaire Phill Gross’ Stock Picks with Huge Upside Potential - Yahoo Finance

Click here to get full coverage on Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights - Business Wire

Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights  Business Wire

Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights - Business Wire

Click here to get full coverage on Is Janux Therapeutics, Inc. (JANX) the Best Small Cap Stock to Buy with the Biggest Upside Potential? - Yahoo Finance

Is Janux Therapeutics, Inc. (JANX) the Best Small Cap Stock to Buy with the Biggest Upside Potential?  Yahoo Finance

Is Janux Therapeutics, Inc. (JANX) the Best Small Cap Stock to Buy with the Biggest Upside Potential? - Yahoo Finance

Click here to get full coverage on Learn to Evaluate (JANX) using the Charts - news.stocktradersdaily.com

Learn to Evaluate (JANX) using the Charts  news.stocktradersdaily.com

Learn to Evaluate (JANX) using the Charts - news.stocktradersdaily.com

Click here to get full coverage on Decoding Janux Therapeutics Inc (JANX): A Strategic SWOT Insight - GuruFocus

Decoding Janux Therapeutics Inc (JANX): A Strategic SWOT Insight  GuruFocus

Decoding Janux Therapeutics Inc (JANX): A Strategic SWOT Insight - GuruFocus

Click here to get full coverage on Janux Therapeutics, Inc. (JANX): Among The Stocks With At Least $30 Million In Insider Spending Recently - Yahoo Finance

Janux Therapeutics, Inc. (JANX): Among The Stocks With At Least $30 Million In Insider Spending Recently  Yahoo Finance

Janux Therapeutics, Inc. (JANX): Among The Stocks With At Least $30 Million In Insider Spending Recently - Yahoo Finance

Click here to get full coverage on Scotiabank Adjusts Janux Therapeutics (JANX) Price Target Amid T - GuruFocus

Scotiabank Adjusts Janux Therapeutics (JANX) Price Target Amid T  GuruFocus

Scotiabank Adjusts Janux Therapeutics (JANX) Price Target Amid T - GuruFocus

Click here to get full coverage on Janux Therapeutics, Inc. (JANX): Among the Oversold Biotech Stocks to Buy Now - Yahoo Finance

Janux Therapeutics, Inc. (JANX): Among the Oversold Biotech Stocks to Buy Now  Yahoo Finance

Janux Therapeutics, Inc. (JANX): Among the Oversold Biotech Stocks to Buy Now - Yahoo Finance

Click here to get full coverage on Is Janux Therapeutics, Inc. (NASDAQ:JANX) the Best Small Cap Stock to Buy Before They Explode? - Yahoo Finance

Is Janux Therapeutics, Inc. (NASDAQ:JANX) the Best Small Cap Stock to Buy Before They Explode?  Yahoo Finance

Is Janux Therapeutics, Inc. (NASDAQ:JANX) the Best Small Cap Stock to Buy Before They Explode? - Yahoo Finance

Click here to get full coverage on Is Janux Therapeutics Inc. (NASDAQ:JANX) the Best Up and Coming Stock to Buy According to Wall Street Analysts? - Yahoo Finance

Is Janux Therapeutics Inc. (NASDAQ:JANX) the Best Up and Coming Stock to Buy According to Wall Street Analysts?  Yahoo Finance

Is Janux Therapeutics Inc. (NASDAQ:JANX) the Best Up and Coming Stock to Buy According to Wall Street Analysts? - Yahoo Finance

Click here to get full coverage on Janux Therapeutics (JANX) Advances Clinical Trials for JANX007 | JANX Stock News - GuruFocus

Janux Therapeutics (JANX) Advances Clinical Trials for JANX007 | JANX Stock News  GuruFocus

Janux Therapeutics (JANX) Advances Clinical Trials for JANX007 | JANX Stock News - GuruFocus

Click here to get full coverage on JANX Stock Hits Record High on Prostate Cancer Study Data - Yahoo Finance

JANX Stock Hits Record High on Prostate Cancer Study Data  Yahoo Finance

JANX Stock Hits Record High on Prostate Cancer Study Data - Yahoo Finance

Click here to get full coverage on Is Janux Therapeutics (JANX) a Worst High-Risk High-Reward Growth Stock to Buy? - Yahoo Finance

Is Janux Therapeutics (JANX) a Worst High-Risk High-Reward Growth Stock to Buy?  Yahoo Finance

Is Janux Therapeutics (JANX) a Worst High-Risk High-Reward Growth Stock to Buy? - Yahoo Finance

Click here to get full coverage on Janux Therapeutics, Inc. (JANX): Among Stocks Receiving the Most Insider Love in March - Yahoo Finance

Janux Therapeutics, Inc. (JANX): Among Stocks Receiving the Most Insider Love in March  Yahoo Finance

Janux Therapeutics, Inc. (JANX): Among Stocks Receiving the Most Insider Love in March - Yahoo Finance

Click here to get full coverage on Janux Therapeutics Raises Massive $402.5M in Oversubscribed Public Offering - Stock Titan

Janux Therapeutics Raises Massive $402.5M in Oversubscribed Public Offering  Stock Titan

Janux Therapeutics Raises Massive $402.5M in Oversubscribed Public Offering - Stock Titan

Click here to get full coverage on Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation - simplywall.st

Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation  simplywall.st

Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation - simplywall.st

Click here to get full coverage on Janux Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary - TradingView

Janux Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary  TradingView

Janux Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary - TradingView

Click here to get full coverage on Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer - Business Wire

Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer  Business Wire

Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer - Business Wire

Click here to get full coverage on Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC - Business Wire

Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC  Business Wire

Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC - Business Wire

Click here to get full coverage on Long Term Trading Analysis for (JANX) - news.stocktradersdaily.com

Long Term Trading Analysis for (JANX)  news.stocktradersdaily.com

Long Term Trading Analysis for (JANX) - news.stocktradersdaily.com

Click here to get full coverage on Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - Business Wire

Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights  Business Wire

Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - Business Wire

Click here to get full coverage on Janux Therapeutics: mCRPC TAM And Promising JANX007’s Phase 1 Data (NASDAQ:JANX) - Seeking Alpha

Janux Therapeutics: mCRPC TAM And Promising JANX007’s Phase 1 Data (NASDAQ:JANX)  Seeking Alpha

Janux Therapeutics: mCRPC TAM And Promising JANX007’s Phase 1 Data (NASDAQ:JANX) - Seeking Alpha

Click here to get full coverage on Leerink cuts Janux Therapeutics price target to $89, keeps Outperform By Investing.com - Investing.com South Africa

Leerink cuts Janux Therapeutics price target to $89, keeps Outperform By Investing.com  Investing.com South Africa

Leerink cuts Janux Therapeutics price target to $89, keeps Outperform By Investing.com - Investing.com South Africa

Click here to get full coverage on Janux Therapeutics: Buoyed By Buyout Speculation (NASDAQ:JANX) - Seeking Alpha

Janux Therapeutics: Buoyed By Buyout Speculation (NASDAQ:JANX)  Seeking Alpha

Janux Therapeutics: Buoyed By Buyout Speculation (NASDAQ:JANX) - Seeking Alpha

Click here to get full coverage on Janux Therapeutics: Hype Breeds Volatility, And That Should Give You Pause (NASDAQ:JANX) - Seeking Alpha

Janux Therapeutics: Hype Breeds Volatility, And That Should Give You Pause (NASDAQ:JANX)  Seeking Alpha

Janux Therapeutics: Hype Breeds Volatility, And That Should Give You Pause (NASDAQ:JANX) - Seeking Alpha

Click here to get full coverage on Janux Therapeutics: Buying For The Promising Pipeline, Holding For The Buyout (NASDAQ:JANX) - Seeking Alpha

Janux Therapeutics: Buying For The Promising Pipeline, Holding For The Buyout (NASDAQ:JANX)  Seeking Alpha

Janux Therapeutics: Buying For The Promising Pipeline, Holding For The Buyout (NASDAQ:JANX) - Seeking Alpha

Click here to get full coverage on Top 11 Small Cap Stocks to Buy with Biggest Upside Potential - Insider Monkey

Top 11 Small Cap Stocks to Buy with Biggest Upside Potential  Insider Monkey

Top 11 Small Cap Stocks to Buy with Biggest Upside Potential - Insider Monkey

Click here to get full coverage on Janux Therapeutics price target lowered to $41 from $62 at Scotiabank - Yahoo Finance

Janux Therapeutics price target lowered to $41 from $62 at Scotiabank  Yahoo Finance

Janux Therapeutics price target lowered to $41 from $62 at Scotiabank - Yahoo Finance

Click here to get full coverage on Insider Sell Alert: Andrew Meyer Sells Shares of Janux Therapeutics Inc (JANX) - GuruFocus

Insider Sell Alert: Andrew Meyer Sells Shares of Janux Therapeutics Inc (JANX)  GuruFocus

Insider Sell Alert: Andrew Meyer Sells Shares of Janux Therapeutics Inc (JANX) - GuruFocus

Click here to get full coverage on Janux Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - simplywall.st

Janux Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag  simplywall.st

Janux Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - simplywall.st

Click here to get full coverage on Biotech Rockets 49% To Record High On 'Unprecedented' Results - Investor's Business Daily

Biotech Rockets 49% To Record High On 'Unprecedented' Results  Investor's Business Daily

Biotech Rockets 49% To Record High On 'Unprecedented' Results - Investor's Business Daily

Click here to get full coverage on Why Janux Therapeutics Crushed the Market Today - The Motley Fool

Why Janux Therapeutics Crushed the Market Today  The Motley Fool

Why Janux Therapeutics Crushed the Market Today - The Motley Fool

Click here to get full coverage on Janux Therapeutics chief business officer sells shares for $107,174 - Investing.com

Janux Therapeutics chief business officer sells shares for $107,174  Investing.com

Janux Therapeutics chief business officer sells shares for $107,174 - Investing.com

Click here to get full coverage on Unknown Billionaire Phill Gross’ 10 Stock Picks with Huge Upside Potential - Insider Monkey

Unknown Billionaire Phill Gross’ 10 Stock Picks with Huge Upside Potential  Insider Monkey

Unknown Billionaire Phill Gross’ 10 Stock Picks with Huge Upside Potential - Insider Monkey

Click here to get full coverage on Cantor Fitzgerald maintains $200 target on Janux Therapeutics stock - Investing.com

Cantor Fitzgerald maintains $200 target on Janux Therapeutics stock  Investing.com

Cantor Fitzgerald maintains $200 target on Janux Therapeutics stock - Investing.com

Click here to get full coverage on Latham Advises on Janux Therapeutics’ US$350 Million Public Offering of Common Stock and Pre-Funded Warrants - Latham & Watkins LLP

Latham Advises on Janux Therapeutics’ US$350 Million Public Offering of Common Stock and Pre-Funded Warrants  Latham & Watkins LLP

Latham Advises on Janux Therapeutics’ US$350 Million Public Offering of Common Stock and Pre-Funded Warrants - Latham & Watkins LLP

Click here to get full coverage on Ra capital management buys $25.3 million in Janux therapeutics stock - Investing.com

Ra capital management buys $25.3 million in Janux therapeutics stock  Investing.com

Ra capital management buys $25.3 million in Janux therapeutics stock - Investing.com

Click here to get full coverage on Janux Therapeutics stock hits 52-week low at $23.72 - Investing.com

Janux Therapeutics stock hits 52-week low at $23.72  Investing.com

Janux Therapeutics stock hits 52-week low at $23.72 - Investing.com

Click here to get full coverage on Janux Therapeutics CEO sells $1 million in stock - Investing.com

Janux Therapeutics CEO sells $1 million in stock  Investing.com

Janux Therapeutics CEO sells $1 million in stock - Investing.com

Click here to get full coverage on 10 Oversold Biotech Stocks to Buy Now - Insider Monkey

10 Oversold Biotech Stocks to Buy Now  Insider Monkey

10 Oversold Biotech Stocks to Buy Now - Insider Monkey

Click here to get full coverage on Janux Therapeutics stock hits 52-week low at $28.92 - Investing.com

Janux Therapeutics stock hits 52-week low at $28.92  Investing.com

Janux Therapeutics stock hits 52-week low at $28.92 - Investing.com

Click here to get full coverage on Buy Rating for Janux Therapeutics Inc: Promising PFS Data and Attractive Valuation - TipRanks

Buy Rating for Janux Therapeutics Inc: Promising PFS Data and Attractive Valuation  TipRanks

Buy Rating for Janux Therapeutics Inc: Promising PFS Data and Attractive Valuation - TipRanks

Click here to get full coverage on Janux Therapeutics: Promising T-Cell Engager Platform In Cancer Therapy (NASDAQ:JANX) - Seeking Alpha

Janux Therapeutics: Promising T-Cell Engager Platform In Cancer Therapy (NASDAQ:JANX)  Seeking Alpha

Janux Therapeutics: Promising T-Cell Engager Platform In Cancer Therapy (NASDAQ:JANX) - Seeking Alpha

Click here to get full coverage on 10 Worst High-Risk High-Reward Growth Stocks To Buy - Insider Monkey

10 Worst High-Risk High-Reward Growth Stocks To Buy  Insider Monkey

10 Worst High-Risk High-Reward Growth Stocks To Buy - Insider Monkey

Click here to get full coverage on symbol__ Stock Quote Price and Forecast - CNN

symbol__ Stock Quote Price and Forecast  CNN

symbol__ Stock Quote Price and Forecast - CNN

Click here to get full coverage on Viking Therapeutics among potential buyout candidates: Oppenheimer - MSN

Viking Therapeutics among potential buyout candidates: Oppenheimer  MSN

Viking Therapeutics among potential buyout candidates: Oppenheimer - MSN

Click here to get full coverage on Insider Sell: David Campbell Sells 15,000 Shares of Janux Therap - GuruFocus

Insider Sell: David Campbell Sells 15,000 Shares of Janux Therap  GuruFocus

Insider Sell: David Campbell Sells 15,000 Shares of Janux Therap - GuruFocus

Click here to get full coverage on Janux Therapeutics CFO sells over $45 million in company stock - Investing.com

Janux Therapeutics CFO sells over $45 million in company stock  Investing.com

Janux Therapeutics CFO sells over $45 million in company stock - Investing.com

Click here to get full coverage on AT&T Updates 2024 Outlook, Joins ZJK Industrial, Janux Therapeutics, Credo Technology Group And Other Big Stocks Moving Higher On Tuesday - Benzinga

AT&T Updates 2024 Outlook, Joins ZJK Industrial, Janux Therapeutics, Credo Technology Group And Other Big Stocks Moving Higher On Tuesday  Benzinga

AT&T Updates 2024 Outlook, Joins ZJK Industrial, Janux Therapeutics, Credo Technology Group And Other Big Stocks Moving Higher On Tuesday - Benzinga

Click here to get full coverage on Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors - Yahoo Finance

Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors  Yahoo Finance

Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors - Yahoo Finance

Click here to get full coverage on Cancer-Drug Maker Janux Therapeutics Weighs Possible Sale - Bloomberg.com

Cancer-Drug Maker Janux Therapeutics Weighs Possible Sale  Bloomberg.com

Cancer-Drug Maker Janux Therapeutics Weighs Possible Sale - Bloomberg.com

Click here to get full coverage on JANX Stock Price and Chart — NASDAQ:JANX - TradingView

JANX Stock Price and Chart — NASDAQ:JANX  TradingView

Janux Therapeutics Inc (JANX)

Price Chart

Key Statistics

Technicals

About JANX

Latest News

Trend Tracker for (JANX) - news.stocktradersdaily.com

Janux Therapeutics (JANX) Reports Q1 EPS Loss, Maintains Strong Cash Position - GuruFocus

Janux Therapeutics, Inc. (JANX): Among Unknown Billionaire Phill Gross’ Stock Picks with Huge Upside Potential - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers